286 related articles for article (PubMed ID: 28228084)
41. Potent antitumoral effects of targeted promoter-driven oncolytic adenovirus armed with Dm-dNK for breast cancer in vitro and in vivo.
Dong X; Qu W; Ma S; Zhu Z; Zheng C; He A; Karlsson A; Xu K; Zheng X
Cancer Lett; 2013 Jan; 328(1):95-103. PubMed ID: 23000515
[TBL] [Abstract][Full Text] [Related]
42. Antitumor effects of oncolytic adenovirus armed with Drosophila melanogaster deoxyribonucleoside kinase in colorectal cancer.
Ma S; Qu W; Mao L; Zhu Z; Jia L; Zhao L; Zheng X
Oncol Rep; 2012 May; 27(5):1443-50. PubMed ID: 22294034
[TBL] [Abstract][Full Text] [Related]
43. A phase I dose-escalation clinical trial of intraoperative direct intratumoral injection of HF10 oncolytic virus in non-resectable patients with advanced pancreatic cancer.
Nakao A; Kasuya H; Sahin TT; Nomura N; Kanzaki A; Misawa M; Shirota T; Yamada S; Fujii T; Sugimoto H; Shikano T; Nomoto S; Takeda S; Kodera Y; Nishiyama Y
Cancer Gene Ther; 2011 Mar; 18(3):167-75. PubMed ID: 21102422
[TBL] [Abstract][Full Text] [Related]
44. Oncolytic viruses and pancreatic cancer.
Hamidi-Sofiani V; Rakhshi R; Moradi N; Zeynali P; Nakhaie M; Behboudi E
Cancer Treat Res Commun; 2022; 31():100563. PubMed ID: 35460973
[TBL] [Abstract][Full Text] [Related]
45. Combined fiber modifications both to target α(v)β(6) and detarget the coxsackievirus-adenovirus receptor improve virus toxicity profiles in vivo but fail to improve antitumoral efficacy relative to adenovirus serotype 5.
Coughlan L; Vallath S; Gros A; Giménez-Alejandre M; Van Rooijen N; Thomas GJ; Baker AH; Cascalló M; Alemany R; Hart IR
Hum Gene Ther; 2012 Sep; 23(9):960-79. PubMed ID: 22708837
[TBL] [Abstract][Full Text] [Related]
46. Adenovirus Receptor Expression in Cancer and Its Multifaceted Role in Oncolytic Adenovirus Therapy.
Hensen LCM; Hoeben RC; Bots STF
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32957644
[TBL] [Abstract][Full Text] [Related]
47. A simplified system for generating oncolytic adenovirus vector carrying one or two transgenes.
Hu ZB; Wu CT; Wang H; Zhang QW; Wang L; Wang RL; Lu ZZ; Wang LS
Cancer Gene Ther; 2008 Mar; 15(3):173-82. PubMed ID: 18157145
[TBL] [Abstract][Full Text] [Related]
48. A hydrogel matrix prolongs persistence and promotes specific localization of an oncolytic adenovirus in a tumor by restricting nonspecific shedding and an antiviral immune response.
Jung BK; Oh E; Hong J; Lee Y; Park KD; Yun CO
Biomaterials; 2017 Dec; 147():26-38. PubMed ID: 28923683
[TBL] [Abstract][Full Text] [Related]
49. Oncolytic adenoviruses and the treatment of pancreatic cancer: a review of clinical trials.
Taylor IP; Lopez JA
J Cancer Res Clin Oncol; 2023 Aug; 149(10):8117-8129. PubMed ID: 37031291
[TBL] [Abstract][Full Text] [Related]
50. Recent advances in oncolytic adenovirus therapies for cancer.
Rosewell Shaw A; Suzuki M
Curr Opin Virol; 2016 Dec; 21():9-15. PubMed ID: 27379906
[TBL] [Abstract][Full Text] [Related]
51. A hypoxia- and telomerase-responsive oncolytic adenovirus expressing secretable trimeric TRAIL triggers tumour-specific apoptosis and promotes viral dispersion in TRAIL-resistant glioblastoma.
Oh E; Hong J; Kwon OJ; Yun CO
Sci Rep; 2018 Jan; 8(1):1420. PubMed ID: 29362367
[TBL] [Abstract][Full Text] [Related]
52. The Efficacy of Oncolytic Adenovirus Is Mediated by T-cell Responses against Virus and Tumor in Syrian Hamster Model.
Li X; Wang P; Li H; Du X; Liu M; Huang Q; Wang Y; Wang S
Clin Cancer Res; 2017 Jan; 23(1):239-249. PubMed ID: 27435398
[TBL] [Abstract][Full Text] [Related]
53. A novel oncolytic adenovirus targeting Wnt signaling effectively inhibits cancer-stem like cell growth via metastasis, apoptosis and autophagy in HCC models.
Zhang J; Lai W; Li Q; Yu Y; Jin J; Guo W; Zhou X; Liu X; Wang Y
Biochem Biophys Res Commun; 2017 Sep; 491(2):469-477. PubMed ID: 28698142
[TBL] [Abstract][Full Text] [Related]
54. Irradiation enhances the therapeutic effect of the oncolytic adenovirus XVir-N-31 in brain tumor initiating cells.
Czolk R; Schwarz N; Koch H; Schötterl S; Wuttke TV; Holm PS; Huber SM; Naumann U
Int J Mol Med; 2019 Oct; 44(4):1484-1494. PubMed ID: 31432139
[TBL] [Abstract][Full Text] [Related]
55. Oncolytic adenovirus expressing interferon alpha in a syngeneic Syrian hamster model for the treatment of pancreatic cancer.
LaRocca CJ; Han J; Gavrikova T; Armstrong L; Oliveira AR; Shanley R; Vickers SM; Yamamoto M; Davydova J
Surgery; 2015 May; 157(5):888-98. PubMed ID: 25731784
[TBL] [Abstract][Full Text] [Related]
56. Virus combinations and chemotherapy for the treatment of human cancers.
Kumar S; Gao L; Yeagy B; Reid T
Curr Opin Mol Ther; 2008 Aug; 10(4):371-9. PubMed ID: 18683102
[TBL] [Abstract][Full Text] [Related]
57. Bioselection Reveals miR-99b and miR-485 as Enhancers of Adenoviral Oncolysis in Pancreatic Cancer.
Rovira-Rigau M; Raimondi G; Marín MÁ; Gironella M; Alemany R; Fillat C
Mol Ther; 2019 Jan; 27(1):230-243. PubMed ID: 30341009
[TBL] [Abstract][Full Text] [Related]
58. Oncolytic Virotherapy: An Advanced Microbial Approach for the Management of Cancer.
Rao MFS; Ahmed B; Qadir MI
Crit Rev Eukaryot Gene Expr; 2024; 34(1):1-13. PubMed ID: 37824388
[TBL] [Abstract][Full Text] [Related]
59. A novel capsid-modified oncolytic recombinant adenovirus type 5 for tumor-targeting gene therapy by intravenous route.
Wang Z; Yu B; Wang B; Yan J; Feng X; Wang Z; Wang L; Zhang H; Wu H; Wu J; Kong W; Yu X
Oncotarget; 2016 Jul; 7(30):47287-47301. PubMed ID: 27323824
[TBL] [Abstract][Full Text] [Related]
60. Anti-cancer Virotherapy in Russia: Lessons from the Past, Current Challenges and Prospects for the Future.
Kolyasnikova NM; Pestov NB; Sanchez-Pimentel JP; Barlev NA; Ishmukhametov AA
Curr Pharm Biotechnol; 2023; 24(2):266-278. PubMed ID: 35578840
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
